Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Cash & Equivalents (2019 - 2025)

aTYR PHARMA's Cash & Equivalents history spans 7 years, with the latest figure at $10.7 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 2.82% year-over-year to $10.7 million; the TTM value through Dec 2025 reached $10.7 million, down 2.82%, while the annual FY2025 figure was $10.7 million, 2.82% down from the prior year.
  • Cash & Equivalents reached $10.7 million in Q4 2025 per ATYR's latest filing, up from $6.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $59.7 million in Q3 2021 to a low of $2.2 million in Q2 2021.
  • Average Cash & Equivalents over 5 years is $13.4 million, with a median of $10.6 million recorded in 2025.
  • Peak YoY movement for Cash & Equivalents: plummeted 89.87% in 2021, then soared 327.27% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $2.3 million in 2021, then soared by 327.27% to $10.0 million in 2022, then skyrocketed by 125.87% to $22.5 million in 2023, then plummeted by 50.96% to $11.1 million in 2024, then decreased by 2.82% to $10.7 million in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Cash & Equivalents are $10.7 million (Q4 2025), $6.1 million (Q3 2025), and $17.2 million (Q2 2025).